RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP cut its stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 65.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 180,465 shares of the company's stock after selling 339,957 shares during the period. Two Sigma Investments LP owned approximately 0.52% of RAPT Therapeutics worth $285,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in RAPT. SG Americas Securities LLC increased its holdings in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after buying an additional 42,636 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of RAPT Therapeutics by 9.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after purchasing an additional 18,558 shares during the last quarter. Callan Family Office LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $92,000. Picton Mahoney Asset Management grew its position in shares of RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $64,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of RAPT Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. UBS Group lowered their price target on shares of RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Finally, HC Wainwright upgraded shares of RAPT Therapeutics to a "strong-buy" rating and set a $6.00 price target on the stock in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, RAPT Therapeutics presently has an average rating of "Hold" and an average target price of $3.00.

RAPT Therapeutics Stock Performance

NASDAQ RAPT traded down $0.05 during mid-day trading on Friday, reaching $1.04. 617,864 shares of the stock were exchanged, compared to its average volume of 1,288,443. RAPT Therapeutics, Inc. has a 1-year low of $0.71 and a 1-year high of $3.83. The business's fifty day simple moving average is $0.92 and its 200 day simple moving average is $1.12. The stock has a market capitalization of $137.58 million, a PE ratio of -0.38 and a beta of -0.11.

Shares of RAPT Therapeutics are set to reverse split before the market opens on Tuesday, June 17th. The 1-8 reverse split was announced on Friday, June 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 16th.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. On average, analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.